76 related articles for article (PubMed ID: 9467283)
1. [Be careful about pseudo-information on cost-effectiveness].
Lindberg M
Lakartidningen; 1998 Jan; 95(3):144. PubMed ID: 9467283
[No Abstract] [Full Text] [Related]
2. [Simvastatin 40 mg as secondary prophylaxis: Effective, tolerable and cost-efficient!].
Hernborg A; Hjemdahl P; Håkansson J
Lakartidningen; 2006 Mar 15-21; 103(11):858, 861; discussion 861-2. PubMed ID: 16613120
[No Abstract] [Full Text] [Related]
3. [The 4S study is analysed. Cholesterol reduction is cost-efficient].
Jönsson B; Johannesson M; Olsson AG
Lakartidningen; 1997 Dec; 94(51-52):4931-4. PubMed ID: 9454018
[No Abstract] [Full Text] [Related]
4. [SBU should investigate what is an evidence-based and cost-effective use of statins].
Hjemdahl P; Allhammar A; Heaton C; Hulting J; Kahan T; Malmström R; Martinsson A; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
Lakartidningen; 2009 Aug 5-18; 106(32-33):1992-4. PubMed ID: 19764381
[No Abstract] [Full Text] [Related]
5. [Cost effectiveness in the Danish health care of ezetemibe co-administration compared to simvastatin].
Keiding H; Hildebrandt P; Alemao E; Davies GM
Ugeskr Laeger; 2008 Jun; 170(26-32):2323-6. PubMed ID: 18570764
[TBL] [Abstract][Full Text] [Related]
6. [Statins and costs of prevented death cases].
Robberstad T
Tidsskr Nor Laegeforen; 1997 Nov; 117(28):4131. PubMed ID: 9441454
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness of statin medications.
Kaplan RM; Golomb BA
Am Psychol; 2001 Apr; 56(4):366-7. PubMed ID: 11330239
[No Abstract] [Full Text] [Related]
8. Effect of splitting simvastatin tablets for control of low-density lipoprotein cholesterol.
Parra D; Beckey NP; Raval HS; Schnacky KR; Calabrese V; Coakley RW; Goodhope RC;
Am J Cardiol; 2005 Jun; 95(12):1481-3. PubMed ID: 15950578
[TBL] [Abstract][Full Text] [Related]
9. [The seemingly lethal simvastatin...].
Lindberg M
Ugeskr Laeger; 2009 Oct; 171(41):3028-9. PubMed ID: 19839131
[No Abstract] [Full Text] [Related]
10. [Pfizer: TLV decision about antilipemic agents is founded on wrong basis].
Brun J; Ohlsson-Onerud A; Sörensen N
Lakartidningen; 2009 Apr 22-28; 106(17):1193-4; discussion 1194. PubMed ID: 19530431
[No Abstract] [Full Text] [Related]
11. [Contribution to statins?].
Heebøll-Nielsen NC; Ahnfeldt-Mollerup I
Ugeskr Laeger; 1998 Sep; 160(37):5376-7. PubMed ID: 9748871
[No Abstract] [Full Text] [Related]
12. A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study.
Badia X; Russo P; Attanasio E
Clin Ther; 1999 Oct; 21(10):1788-96. PubMed ID: 10566573
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe.
Perkerson KA; Gillespie EL; Coleman CI
Conn Med; 2005 Jan; 69(1):19-22. PubMed ID: 15736370
[No Abstract] [Full Text] [Related]
14. [Influence of pharmacologic cholesterol-lowering on the utilization of resources in health care--Significance of the Scandinavian Simvastatin Survival Study for cost reduction under Swiss conditions].
Steurer J
Schweiz Med Wochenschr; 1998 Jul; 128(29-30):1150-1. PubMed ID: 9715503
[No Abstract] [Full Text] [Related]
15. Cost effectiveness of coronary prevention.
Szucs TD; März W
Eur Heart J; 1999 Feb; 20(4):317-8. PubMed ID: 10099929
[No Abstract] [Full Text] [Related]
16. [The new debate on cholesterol: is the lowest level the best?].
Olsson AG
Lakartidningen; 1999 Feb; 96(6):648-52. PubMed ID: 10087815
[No Abstract] [Full Text] [Related]
17. Twenty-four more days.
Goldstein MR
Am J Cardiol; 1998 Sep; 82(5):703-4. PubMed ID: 9732913
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
[TBL] [Abstract][Full Text] [Related]
19. [Drug prescription and drug subsidizing].
Eggen AE
Tidsskr Nor Laegeforen; 2009 Nov; 129(22):2390. PubMed ID: 19935952
[No Abstract] [Full Text] [Related]
20. [Also elderly patients with hyperlipidemia and coronary disease need lipid lowering agents].
Hellénius ML
Lakartidningen; 2001 Sep; 98(39):4188-90. PubMed ID: 11680152
[No Abstract] [Full Text] [Related]
[Next] [New Search]
